John W Haukeland

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies
    John Willy Haukeland
    Department of Gastroenterology Research Institute for Internal Medicine, Oslo University Hospital Ulleval, PB 4950, 0424 Oslo, Norway
    Eur J Endocrinol 166:503-10. 2012
  2. ncbi Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
    John Willy Haukeland
    Department of Gastroenterology, Ulleval University Hospital, Oslo, Norway
    Scand J Gastroenterol 40:1469-77. 2005
  3. ncbi Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
    John Willy Haukeland
    Faculty Division, Aker University Hospital, University of Oslo, Oslo, Norway
    J Hepatol 44:1167-74. 2006
  4. ncbi Incidence rates and causes of cirrhosis in a Norwegian population
    John W Haukeland
    Faculty Division, Aker University Hospital, University of Oslo, Oslo, Norway
    Scand J Gastroenterol 42:1501-8. 2007
  5. ncbi ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis
    John W Haukeland
    Department of Gastroenterology, Aker University Hospital, University of Oslo, Norway
    Scand J Gastroenterol 43:1241-8. 2008
  6. ncbi Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial
    John Willy Haukeland
    Faculty Division, Department of Gastroenterology, Aker University Hospital, Trondheimsveien 235, Oslo, Norway
    Scand J Gastroenterol 44:853-60. 2009
  7. ncbi A complex role of activin A in non-alcoholic fatty liver disease
    Arne Yndestad
    Research Institute for Internal Medicine, Rikshospitalet, Oslo University Hospital, Oslo, N 0027, Norway
    Am J Gastroenterol 104:2196-205. 2009

Detail Information

Publications7

  1. ncbi Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies
    John Willy Haukeland
    Department of Gastroenterology Research Institute for Internal Medicine, Oslo University Hospital Ulleval, PB 4950, 0424 Oslo, Norway
    Eur J Endocrinol 166:503-10. 2012
    ..Fetuin A has been associated with insulin resistance and the metabolic syndrome. We therefore explored the role of fetuin A in nonalcoholic fatty liver disease (NAFLD)...
  2. ncbi Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
    John Willy Haukeland
    Department of Gastroenterology, Ulleval University Hospital, Oslo, Norway
    Scand J Gastroenterol 40:1469-77. 2005
    ..Our aim was to estimate these frequencies. We characterize a population with NAFLD, with special emphasis on insulin resistance and the metabolic syndrome, and study possible predictors for different stages of the disease...
  3. ncbi Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
    John Willy Haukeland
    Faculty Division, Aker University Hospital, University of Oslo, Oslo, Norway
    J Hepatol 44:1167-74. 2006
    ..To elucidate the role of systemic inflammation in nonalcoholic fatty liver disease (NAFLD)...
  4. ncbi Incidence rates and causes of cirrhosis in a Norwegian population
    John W Haukeland
    Faculty Division, Aker University Hospital, University of Oslo, Oslo, Norway
    Scand J Gastroenterol 42:1501-8. 2007
    ..To investigate the incidence rate and causes of cirrhosis in a Norwegian population. We also sought to assess the degree of underreporting of cirrhosis to the Norwegian Death Registry...
  5. ncbi ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis
    John W Haukeland
    Department of Gastroenterology, Aker University Hospital, University of Oslo, Norway
    Scand J Gastroenterol 43:1241-8. 2008
    ....
  6. ncbi Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial
    John Willy Haukeland
    Faculty Division, Department of Gastroenterology, Aker University Hospital, Trondheimsveien 235, Oslo, Norway
    Scand J Gastroenterol 44:853-60. 2009
    ..The purpose of this study was to conduct a randomized, double-blind, placebo-controlled trial to test whether metformin improves liver histology in patients with non-alcoholic fatty liver disease...
  7. ncbi A complex role of activin A in non-alcoholic fatty liver disease
    Arne Yndestad
    Research Institute for Internal Medicine, Rikshospitalet, Oslo University Hospital, Oslo, N 0027, Norway
    Am J Gastroenterol 104:2196-205. 2009
    ..Recent studies suggest that activin A, a member of the transforming growth factor (TGF) superfamily, is involved in the pathogenesis of liver disorders. We sought to explore its possible role in non-alcoholic fatty liver disease (NAFLD)...